Century Therapeutics, Inc.
IPSC
$2.41
$0.114.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,556.51% | 4,121.12% | 5,489.03% | 8,286.79% | 194.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,556.51% | 4,121.12% | 5,489.03% | 8,286.79% | 194.85% |
| Cost of Revenue | -10.80% | 5.17% | 14.96% | 21.01% | 15.68% |
| Gross Profit | 113.42% | 108.20% | 104.36% | 105.00% | -11.25% |
| SG&A Expenses | -13.41% | -8.66% | -5.95% | -4.29% | -3.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.42% | 1.66% | 9.40% | 14.06% | 10.38% |
| Operating Income | 88.50% | 82.47% | 77.80% | 77.04% | -7.09% |
| Income Before Tax | 92.27% | 81.11% | 83.66% | 84.82% | 7.43% |
| Income Tax Expenses | -103.80% | 307.96% | 796.06% | 165.58% | -4.78% |
| Earnings from Continuing Operations | 92.44% | 79.62% | 82.28% | 83.56% | 7.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.44% | 79.62% | 82.28% | 83.56% | 7.39% |
| EBIT | 88.50% | 82.47% | 77.80% | 77.04% | -7.09% |
| EBITDA | 98.08% | 91.37% | 86.54% | 86.25% | -7.68% |
| EPS Basic | 93.52% | 83.42% | 86.35% | 87.34% | 29.57% |
| Normalized Basic EPS | 94.60% | 90.26% | 88.05% | 88.52% | 18.81% |
| EPS Diluted | 93.26% | 82.96% | 85.94% | 87.09% | 29.33% |
| Normalized Diluted EPS | 94.55% | 90.21% | 88.00% | 88.48% | 18.81% |
| Average Basic Shares Outstanding | 10.02% | 19.04% | 29.77% | 40.35% | 32.53% |
| Average Diluted Shares Outstanding | 10.04% | 19.07% | 29.80% | 40.38% | 32.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |